Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Amylin (Islet amyloid polypeptide, AIPP(34-70)) is a 37-resi...

Class:IdSummation:9733270
_displayNameAmylin (Islet amyloid polypeptide, AIPP(34-70)) is a 37-resi...
_timestamp2021-06-02 13:00:17
created[InstanceEdit:9733281] Jassal, Bijay, 2021-06-02
literatureReference[LiteratureReference:9733278] Pramlintide in the treatment of diabetes mellitus
[LiteratureReference:9733277] Amylin structure-function relationships and receptor pharmacology: implications for amylin mimetic drug development
textAmylin (Islet amyloid polypeptide, AIPP(34-70)) is a 37-residue peptide hormone which belongs to the calcitonin peptide family. It is cosecreted with insulin from pancreatic β-cells and plays a role in glycemic regulation by preventing post-prandial spikes in blood glucose levels. Its effects are mediated via binding to three distinct receptor complexes containing the calcitonin receptor, plus one of three receptor activity-modifying proteins, RAMP1, RAMP2, or RAMP3.

Pramlintide is a synthetic analogue of human amylin with proline substitutions in positions 25, 26 and 29. Its actions are mediated through calcitonin-RAMP receptor complexes (Gingell et al. 2014). Pramlintide is approved for use in patients with both diabetes mellitus type 1 and diabetes mellitus type 2 (Schmitz et al. 1997, Edelman et al. 2008). Structure-function relationships of amylin are being used for the development of newer amylin mimetic drug (Bower & Hay 2016).
(summation)[Reaction:9733292] AMY1-3 bind pramlintide [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by Amylin (Islet amyloid polypeptide, AIPP(34-70)) is a 37-resi... (9733270)
Follow Reactome